The US Food and Drug Association has granted tentative approval to Strides Arcolab's adenosine injection, the generic equivalent of Astellas Pharmaceuticals' Adenoscan.
According to a company release, the product will be launched upon expiry of applicable innovator patents. Upon approval, Adenosine will be launched under the partnership between Strides and Sagent Pharmaceuticals wherein Strides is developing and supplying more than 25 injectable products for the US market, which will be marketed by Sagent, it added.
Meanwhile, IMS data indicates that the 2009 US innovator market for these adenosine presentations approximated $124 million. Shares of Strides gained nearly 3 per cent on the Bombay Stock Exchange on Thursday, At 12 noon, the shares were trading at Rs 363.
